Phase 2 Clinical Trial of CartiLife® in the United States
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the safety and efficacy of implanting pellet-type extracellular matrix-associated
autologous chondrocytes (CartiLife®) obtained by cultivating costal chondrocytes of the
subject with articular cartilage defects of the knee as a result of trauma or degeneration.